logo
Plus   Neg
Share
Email

Altimmune Submits IND Application For AdCOVID Intranasal COVID-19 Vaccine - Quick Facts

Altimmune, Inc. (ALT), a clinical-stage biopharmaceutical company, said Wednesday that it has submitted an Investigational New Drug or IND application to the U.S. Food and Drug Administration (FDA) to commence a Phase 1 clinical study of its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.

AdCOVID is designed to stimulate a broad immune response including both systemic immunity (neutralizing antibody) and local immunity (mucosal IgA and resident memory T cells) in the nasal cavity and respiratory tract.

Altimmune noted that the single-dose nasal spray offers greater ease and comfort of administration and positions AdCOVID as a differentiated vaccine candidate for adults and children.

According to the company, AdCOVID is capable of stimulating an additional and specialized type of immunity, local nasal mucosal immunity, that is believed to be critical for preventing further transmission of the virus.

"We've made exceptional progress advancing AdCOVID and are on track to begin a Phase 1 clinical study this year, with a data readout anticipated in the first quarter of 2021. While the progress being reported with current vaccines is very encouraging, many in the scientific and medical communities agree that there is continued need for next-generation vaccines that offer significant enhancements," said Vipin Garg, President and Chief Executive Officer of Altimmune.

Altimmune noted that the FDA, in a recent pre-IND meeting, agreed to the overall Phase 1 study design and patient population, as well as plans for manufacturing and product testing of AdCOVID.

Further, the FDA confirmed that additional nonclinical studies were not required and that the toxicology data previously submitted and reviewed for Altimmune's NasoShield and NasoVAX intranasal vaccine candidates support the clinical development of AdCOVID.

No additional toxicology studies are required before the start of the Phase 1 trial.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pfizer Inc. and BioNTech SE Monday announced that they will supply an additional 100 million doses of COMIRNATY, the companies' COVID-19 vaccine, to the 27 European Union member states in 2021. The agreement follows the European Commission's decision to exercise its option to purchase an additional 100 million doses under its expanded Advanced Purchase Agreement signed on February 17. Prineville, Oregon-based Creative Foods Inc. is recalling two Bueno coffee substitute gluten-free products for the possible presence of undeclared allergens, the U.S. Food and Drug Administration said. The recall involves Bueno Coffee Substitute Creamy Hazelnut and Bueno Coffee Substitute Pecan Praline. They both may contain undeclared peanut, hazelnut, and/or barley, which contains gluten. Toyota has unveiled an all-electric SUV concept named "Toyota bZ4X Concept." It is the first of a new battery electric vehicle or BEV line-up under the new Toyota "bZ" - Beyond Zero brand.
Follow RTT